Arterial Occlusive Diseases  >>  niacin extended-release formulation  >>  Phase 4
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
niacin extended-release formulation / Generic mfg.
NCT00590629: Benefit of Elevation of HDL-C on Cardiovascular Outcomes in Women

Completed
4
43
US
Niaspan
Cedars-Sinai Medical Center, General Clinical Research Center (GCRC), Kos Pharmaceuticals
Coronary Artery Disease
11/05
11/05
HALTS, NCT00397657: Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclerosis

Checkmark Data
May 2012 - May 2012: Data
Terminated
4
400
US
extended release niacin, ezetimibe
Walter Reed Army Medical Center, Abbott
Atherosclerosis
08/09
10/09
NCT01308203: Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease

Terminated
4
32
RoW
Extended release niacin/laropiprant, placebo
Daniel A. Siniawski, Merck Sharp & Dohme LLC
Coronary Artery Disease, Dyslipidemias
01/13
01/13

Download Options